Cerapedics Board of Directors

Antony Koblish

Anthony Koblish is a medical device entrepreneur with 25 years of experience who has served on the Cerapedics board of directors since 2013. He is currently co-founder, president and CEO of TELA Bio, a biosurgical reconstruction company. Prior to founding TELA Bio, Mr. Koblish was president and CEO of Orthovita, a publicly traded orthobiologics and biosurgery medical device company, where he helped grow the company’s valuation from $30 million to a $316 million sale to Stryker Corporation.

Glen Kashuba

Glen Kashuba has over 30 years of executive management experience leading medical device companies. Prior to becoming CEO in 2013, Glen served as the Worldwide President of Spine & Bone Healing Technologies, Inc., a Biomet company, and concurrently served as Senior Vice President on Biomet’s Worldwide Operating Board, encompassing Biomet’s orthopedics, spine, trauma, biologics and sports medicine businesses. He also served as Worldwide President for Biomet Spine and Trauma. During his tenure at Biomet, he launched more than 25 new products. Prior to Biomet, Glen held a number of division president roles at Johnson & Johnson, including Worldwide President of Cordis Endovascular, Cordis Neurovascular and Codman Neuro Sciences, and U.S. President of DePuy Spine.

Kenneth Abramowitz

Kenneth Abramowitz is a co-founder and Managing General Partner of NGN Capital. He joined NGN Capital from The Carlyle Group in New York where he was Managing Director from 2001 to 2003, focused on U.S. buyout opportunities in the healthcare industry. Beginning July 2003, he transitioned to Senior Advisor at Carlyle in order to devote the time necessary to create a dedicated healthcare fund on behalf of Carlyle. Prior to joining Carlyle, Mr. Abramowitz worked as an Analyst at Sanford C. Bernstein & Co. where he covered the medical-supply, hospital-management and HMO industries for 23 years, after which he was an EGS Securities Healthcare Fund Manager. He was voted top hospital supply and/or service analyst on the Institutional Investor Magazine “All-America Research Team” during 15 out of 20 years between 1980-2000 and made “The Team” for both healthcare services and medical supplies for 9 years since 1987.

Douglas Kohrs

Douglas Kohrs has 35 years of experience in the medical device industry as a founder, board member, and executive of many innovative companies and non-profit organizations. He is currently managing director of Responsive Arthroscopy, a company focused on value-based healthcare solutions for sports medicine. Prior to Responsive Arthroscopy, Mr. Kohrs founded Responsive Orthopedics, which was acquired by Medtronic in 2016. He also has served as president and CEO of both organizations. He currently serves on the board of directors of six entities and is the president of the Foundation for Essential Needs, a non-profit focused on eradicating hunger.

Chau Khuong

Chau Khuong is a Private Equity Partner with OrbiMed, a leading investment firm dedicated exclusively to the healthcare sector and holding over $14 billion in assets under management. Over his venture capital career, Mr. Khuong has invested in drugs and therapeutic devices across a range of disease areas from oncology to infectious diseases to ophthalmology.  Prior to OrbiMed, he developed skills in start-up operations and business development at Veritas Medicine, Inc. and in basic immunology research at the Yale School of Medicine and Massachusetts General Hospital.

Han Lee, PhD

Han Lee, PhD is currently a Senior Director within AstraZeneca’s Corporate Development and Ventures group, having responsibility for mergers and acquisitions, transformative deals, and strategic equity investments. Prior to AstraZeneca, Dr. Lee was an integral part of two biotech start-ups that both had successful exits and was a part of entrepreneurial teams that have raised over $100 million in financing deals.

Andrew Tofe, PhD

Andrew Tofe, PhD has over forty years of experience in developing and commercializing diagnostic and therapeutic products for bone disease and bone repair. This research and work in bone includes over 50 publications and patents. Dr. Tofe founded and served as President and Chief Executive Officer of CeraMed Dental, where he developed and brought to market three different types of bone substitutes, OsteoGraf®/N in 1990, OsteoGraf®/LD in 1994, PepGen P-15™ in 1999, and PepGen P-15 Flow in 2001. Dr. Tofe served as President and Chief Executive Officer from the transition of CeraMed Dental into Cerapedics, Inc until 2006.